MedPath

Comparison of the effect of Yasmin and Cyproteron compound on metabolic syndrome in women with confirmed polycystic ovary syndrome

Phase 3
Conditions
Metabolic Syndrome.
Polycystic ovarian syndrome
Registration Number
IRCT201204171760N17
Lead Sponsor
Vice Chancellor for Research and Technology, Babol University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
Female
Target Recruitment
60
Inclusion Criteria

18-35 years old nonsmoker women with polycystic ovary syndrome and metabolic syndrome. Exclusion criteria: hyperprolactinemia; hypothyroidism; diabetes; doing regular intense exercise; taking diet or herbal treatment, non-steroidal anti-inflammatory drug, diuretics, or hormone therapy during last 3 months.

Exclusion Criteria

Not provided

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Improvement in indices of metabolic syndrome. Timepoint: After cessation of treatment. Method of measurement: Clinical examination, lab.
Secondary Outcome Measures
NameTimeMethod
Side effects of drugs (such as complaints of headaches and spoting). Timepoint: During drug use. Method of measurement: Self-reported.
© Copyright 2025. All Rights Reserved by MedPath